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Abstract 
We report the case of a 57-year-old patient
with  multiple  myeloma,  characterized  by
extramedullary involvement of the rectum at
presentation.  Malignant  plasma  cells  were
found  to  produce  carcinoembryonic  antigen
(CEA), a tumor antigen more commonly asso-
ciated with rectal adenocarcinomas.
Introduction
Multiple myeloma (MM) is a rare tumor. It
represents about 1% of all malignancies. Its
common clinical manifestations are summa-
rized  by  the  acronym  CRAB:  hyperCalcemia,
Renal  insufficiency,  Anemia,  and  Bone
lesions.
1 The  presence  of  extramedullary
involvement in MM patients is a rare clinical
manifestation,  found  in  only  4.6%  of  cases.
This  event  is  usually  associated  with  poor
prognosis.
2We previously published the largest
series  of  MM  involving  the  gastrointestinal
(GI)  tract,  describing  24  cases  of  extra-
medullary involvement of the GI tract in a data-
base of 2,584 MM patients. The rectum was the
involved  organ  in  only  2  of  them.
3 Here  we
report a case of rectal involvement by MM in
which  the  malignant  plasma  cells  produced
serum  carcinoembryonic  antigen  (CEA),  a
tumor marker more commonly associated with
rectal adenocarcinomas.
Case Report
A 57-year old Caucasian male with history of
Crohn’s disease was diagnosed with a rectal
tumor.  A  surveillance  colonoscopy  found  an
ulcerated non-obstructing rectal mass, non-cir-
cumferential, 3 cm in length, with a macro-
scopic appearance of cancer (Figure 1). 
Initially, the suspected diagnosis was rectal
adenocarcinoma,  not  only  because  of  the
anatomical  location,  but  also  because  the
serum carcinoembryonic antigen (CEA) level
was  elevated  at  10.5  ng/mL  (normal,  <3).
Biopsy showed sheets of epithelioid cells with
pleomorphic  nuclei  and  prominent  nucleoli
(Figure 2). 
At  the  immunostaining  profile,  cells  were
positive for CD138 and negative for CKAE1/3,
CAM5.2, CK5/6, CK7, CK20, CD45, CD3, CD30,
CD20, CD56, p63, PLAP, HMB45, S-100, synap-
tophysin, and chromogranin. Special stain for
mucin was negative. The diagnosis of plasma-
cytoma was confirmed by chromogenic in situ
hybridization (CISH), which showed monotyp-
ic plasma cells, positive for λ- and negative for
κ-mRNA (Figure 3). 
Laboratory  tests  provided  the  following
results:  serum  immunofixation  positive  for
monoclonal IgG-λ proteins, serum IgG 1,820
mg/dL (normal, 700-1600), M component 0.8
g/dL, serum free λlevel 3.23 mg/dL (normal,
0.57-2.63),  urine  proteins  <100  mg  over  24
hours, and β2-microglobulin 2.91 mg/L (nor-
mal, <2.5). Bone marrow biopsy showed only
2% plasma cells, polyclonal by flow cytometry.
Multiple lytic bone lesions were evident at both
skeletal  survey  and  PET  scan.  Patient  was
started on corticosteroids and radiation thera-
py (RT), with the plan for further induction
therapy and autologous stem cell transplanta-
tion. CEA normalized 2 months after the com-
pletion of RT.
Figure 2. Histological section of the rectal
tumor stained with hematoxylin and eosin.
Figure 3. Chromogenic in situ hybridiza-
tion  of  the  tumor  cells  for  κ-  and  λ-
immunoglobulin  light  chains,  and
immunohistochemical staining for CEA.
Figure  1.  Gross  appearance  of  the  rectal
tumor at colonoscopy.
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Discussion
MM involving the GI tract should be distin-
guished from primary extramedullary plasma-
cytomas  (PEMP),  which  are  extraosseous
tumors  of  monoclonal  plasma  cells  without
concomitant bone marrow infiltration. These
are highly curable tumors, exquisitely sensi-
tive  to  RT.
4 Our  patient  had  extramedullary
involvement of the rectum in the context of
MM, an event seen in only 2 of 2,584 consecu-
tive MM cases.
3
The  presence  of  Crohn’s  disease  in  our
patient  may  be  an  unfortunate  coincidence,
but one can speculate that the chronic inflam-
mation and immune stimulation produced by
the Crohn’s disease predisposed to the devel-
opment  of  MM.  Alternatively,  MM  could  be
related  to  the  chronic  immunosuppressive
therapy used to control Crohn’s disease in our
patient, i.e., azathioprine. Whether coinciden-
tal or not, the association between inflamma-
tory  bowel  disease  and  MM  is  rare:  only  11
cases have been described in the medical liter-
ature since 1964.
5,6
Another interesting aspect of our case was
the  elevation  of  the  tumor  marker  CEA.
Crohn’s  disease  may  occasionally  raise  CEA
levels, but the immunohistochemical staining
of the rectal plasmacytoma in our case sug-
gests  the  direct  production  of  CEA  by  the
malignant plasma cells (Figure 3). CEA is one
of the first known tumor antigens. It is a glyco-
protein  belonging  to  the  immunoglobulin
superfamily, and it is involved in cell-cell adhe-
sion.
7 It is not a specific marker, as elevated
values may be found in a wide range of neo-
plasms, including carcinomas of colon, rectum,
stomach, pancreas, lung, and breast.
8 Although
neoplastic plasma cells can frequently express
other members of the CEA family, such as CEA-
CAM1 (CD66a),
9 they usually do not produce
CEA.
10,11 The first case of a MM patient with
high  serum  levels  of  CEA  was  described  by
Kaito et al. in 2007.
12 To our knowledge, our
case is the first reported instance of MM pre-
senting with an extramedullary involvement of
the  rectum  and  associated  with  an  elevated
serum level of CEA. Our report illustrates the
need for tissue biopsy and adequate pathology
even in those cases that may be considered
obvious by clinical oncologists. In fact, without
the  CISH  studies,  the  presence  of  a  rectal
tumor  associated  with  high  CEA  level  could
have been interpreted as adenocarcinoma, and
patient could have received incorrect therapy. 
We do not know the molecular mechanism
that  enables  MM  cells  to  produce  CEA.
Conventional  cytogenetic  analysis  of  plasma
cells in our patient did not identify abnormali-
ties at 19q13.2, the chromosomal region con-
taining the CEA gene. It is possible that other
cases of MM produce CEA, as this marker is
not routinely measured in MM. We are current-
ly screening our cases of MM and plasma cell
leukemia for this tumor antigen, in order to
estimate the actual frequency of CEA produc-
tion among plasma cell neoplasms. 
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